Imidazo[1,2-a]pyrazines as novel PI3K inhibitors

  • Bioorg Med Chem Lett. 2012 Mar 1;22(5):1874-8. doi: 10.1016/j.bmcl.2012.01.074.
Sonia Martínez González  1 ,  Ana Isabel Hernández ,  Carmen Varela ,  Sonsoles Rodríguez-Arístegui ,  Rosa María Alvarez ,  Ana Belén García ,  Milagros Lorenzo ,  Virginia Rivero ,  Julen Oyarzabal ,  Obdulia Rabal ,  James R Bischoff ,  Maribel Albarrán ,  Antonio Cebriá ,  Patricia Alfonso ,  Wolfgang Link ,  Jesús Fominaya ,  Joaquín Pastor
Affiliations
  • 1. Experimental Therapeutics Program, Spanish National Cancer Research Centre (CNIO). C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
PMID: 22325943 DOI: 10.1016/j.bmcl.2012.01.074
Abstract

Phosphoinositide-3-kinase (PI3K) is an important target for Cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2-a]pyrazines as PI3K inhibitors.

Products